Sourav Kole

Sourav joined Dolby Family Ventures as Managing Director of Life Sciences in 2022, where he invests in early-stage neuro companies with particular focus on Alzheimer’s Disease and broadly neurodegeneration, clinical depression and broadly psychiatry, and neurotech. Sourav is a board director of MindImmune Therapeutics and Reservoir Neuroscience and a board observer of Libra Therapeutics, Neurotherapia, Paros Bio, Quralis, and Therini.

Prior to Dolby Family Ventures, Sourav was at Verily (fka Google Life Sciences) as the business lead for programs and partnerships for a wide-range of next-generation technologies at the convergence of life sciences and data science. This includes programs with Allergan, the Broad Institute, Gilead, Procter & Gamble, Verb Surgical (acquired by Johnson & Johnson) and Verily’s efforts towards the opioid epidemic and the COVID-19 pandemic (helping to test 2M+ people between March to July 2020).

Prior to Verily, Sourav was at Varian (previously, NYSE: VAR), where he enabled the strategic transformation of the company. At Varian, Sourav created corporate strategy, executed towards that strategy via $2B of M&A, partnerships, and equity investments, cofounded a venture capital arm, grew the ~$250M China business while working in China, and led the rollup of interventional oncology assets to create a new business unit. Varian was acquired by Siemens Healthineers for $16.4B.

Prior to Varian, Sourav built, consulted for, and invested in a number of early-stage healthcare companies. Successful exits across his investing experiences include Arterys (acquired by Tempus), Fusion Pharma (NASDAQ: FUSN), Grail (acquired by Illumina), Health Catalyst (NASDAQ: HCAT), Instructure (NYSE: INST), Lineagen (acquired by Bionano Genomics), Lyft (NASDAQ: LYFT), Zebra Medical (acquired by Nanox).

Sourav started his career as an entrepreneur by cofounding Xenocor, which commercializes single-use, small footprint laparoscopy enabling widespread access to minimally invasive surgery. By training, Sourav has a PhD in Biomedical Engineering from the University of Utah, where he was a Lassonde Scholar. His doctoral research focused on developing imaging biomarkers for neurodegenerative diseases, specifically Alzheimer’s Disease. Sourav has BS in Biomedical Engineering with a specialization in Electrical Engineering from Penn State.